HTR2B Antibody

What is HTR2B and why is it important to study?

HTR2B (5-hydroxytryptamine receptor 2B) is a G-protein coupled receptor belonging to the serotonin receptor family. In humans, the canonical protein has 481 amino acid residues with a molecular mass of approximately 54.3 kDa. It is primarily localized in the cell membrane and is ubiquitously expressed across various tissue types . HTR2B is crucial for chemical synaptic transmission and 5-HT (serotonin) signaling, which is involved in diverse physiological processes including sleep regulation, mood, appetite control, anxiety modulation, pain perception, and cognition . Studying HTR2B is particularly important due to its emerging roles in cancer immunology, tumor progression, and as a potential therapeutic target in conditions such as nonfunctioning pituitary adenomas .

What are the common applications for HTR2B antibodies in research?

HTR2B antibodies are employed in multiple immunodetection techniques to study the expression, localization, and function of the 5-hydroxytryptamine receptor 2B. The most widely used applications include:

• Western Blot: For detecting and quantifying HTR2B protein expression in tissue or cell lysates

• Immunohistochemistry (IHC): For visualizing HTR2B distribution in tissue sections

• Immunofluorescence (IF): For subcellular localization and co-localization studies

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of HTR2B

• Flow Cytometry: For analyzing HTR2B expression on cell surfaces

The selection of application should be guided by the specific research question and experimental design.

What are the key regions of HTR2B targeted by commercially available antibodies?

Commercial HTR2B antibodies target various epitopes across the protein structure, each offering different advantages for specific applications:

The choice of epitope region can significantly impact experimental outcomes. N-terminal targeting antibodies are particularly valuable for detecting the receptor in its native conformation on cell surfaces, while C-terminal antibodies may better recognize denatured forms of the protein in Western blots .

What species reactivity should be considered when selecting HTR2B antibodies?

HTR2B gene orthologs have been reported in multiple species, including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken . When selecting an antibody, consider the following species reactivity patterns:

• Human-specific antibodies: Most common, particularly those targeting amino acids 15-64

• Cross-reactive antibodies: Available for human, mouse, and rat (particularly useful for comparative studies)

• Broader reactivity: Some antibodies react with human, cow, dog, guinea pig, pig, and horse HTR2B

Always verify species reactivity in the antibody documentation and consider validating cross-reactivity experimentally if working with less common model organisms.

How can I validate the specificity of HTR2B antibodies for my research?

Validating antibody specificity is critical for ensuring reliable experimental results. For HTR2B antibodies, consider implementing these validation approaches:

• Blocking peptide experiments: Pre-incubate the antibody with its immunizing peptide before application. This should eliminate specific staining, as demonstrated in Western blot analyses of mouse brain, rat brain, rat uterus, and human SH-SY5Y neuroblastoma cell lysates .

• Knockout validation: Use CRISPR/Cas9-generated HTR2B knockout cells (HTR2B-/-) as negative controls. This approach has been successfully employed with MC38 cell lines transfected with SR-2B KO CRISPR/Cas9 plasmid .

• Multi-technique confirmation: Verify HTR2B detection across different methodologies (e.g., if observed in Western blot, confirm with immunofluorescence).

• Antibody comparison: Test multiple antibodies targeting different epitopes of HTR2B to confirm consistent detection patterns.

• Expression correlation: Compare antibody detection with mRNA expression data or proteomics findings.

This multi-faceted validation strategy substantially increases confidence in antibody specificity and experimental outcomes.

What are the molecular mechanisms through which HTR2B influences tumor microenvironments?

Recent research has revealed complex roles for HTR2B in tumor biology and immunomodulation:

HTR2B expression correlates with distinct immunological signatures in tumor microenvironments. Deconvolution of RNA-seq datasets using Tumor IMmune Estimation Resource (TIMER) 2.0 demonstrated that tumors with high HTR2B expression (HTR2B-high cohort) show:

• Enrichment of macrophages and monocytes

• Upregulation of T-cell suppressive pathways

• Enhanced angiogenesis and epithelial-mesenchymal transition

• Activated serotonin receptor signaling and TGF-β receptor signaling

In contrast, the HTR2B-low cohort exhibited:

• Enrichment of T, B, and NK cells

• More effective cytotoxic T lymphocyte (CTL) responses

These findings suggest HTR2B may create an immunosuppressive tumor microenvironment by altering the balance of pro-inflammatory and anti-inflammatory immune cells. Importantly, antagonizing HTR2B has been shown to drive antigen-specific T-cell responses against tumors, but only in the presence of tumor antigens and functional effector immune cells .

How do HTR2B antagonists synergize with immunotherapy and chemotherapy in cancer treatment?

HTR2B antagonists have demonstrated promising synergistic effects with both immunotherapies and conventional chemotherapies:

Immunotherapy combinations:
HTR2B antagonists administered alongside immune checkpoint blockers (anti-PD1, anti-PD-L1, or anti-CTLA4 monoclonal antibodies) at suboptimal doses (50 μg/mice every 4th day) significantly enhanced tumor growth reduction compared to either therapy alone. This combination therapy substantially increased the proportion of IFNγ+granzyme B+ cytotoxic effector CD8 T cells within tumors, indicating a potentiated T cell response .

Chemotherapy combinations:
HTR2B antagonists have been effectively combined with FDA-approved first and second-line chemotherapeutic drugs used in colorectal adenocarcinoma (COAD), including:

• Oxaliplatin

• 5-fluorouracil (5-FU)

• Irinotecan

These combinations target cancer cell proliferation while simultaneously generating potent anti-tumor immune responses, representing a dual-action therapeutic approach.

What is the role of HTR2B in nonfunctioning pituitary adenomas (NFPAs) and how does it impact treatment strategies?

Recent studies have uncovered HTR2B as a critical regulator in nonfunctioning pituitary adenomas (NFPAs):

Elevated HTR2B expression has been detected in NFPA samples and is associated with increased tumor survival. Mechanistically, HTR2B functions through the Gαq/PLC/PKCγ/STAT3 signaling axis:

• HTR2B activation triggers the Gαq/PLC/PKC pathway

• PKC-γ directly interacts with STAT3, leading to STAT3 phosphorylation and nuclear translocation

• Activated STAT3 promotes tumor cell proliferation and survival

Treatment implications:

• HTR2B inhibition (using PRX-08066) blocks STAT3 phosphorylation and nuclear translocation

• Cabergoline (CAB), a common dopamine agonist, can paradoxically activate pSTAT3 via HTR2B, limiting its therapeutic efficacy as a standalone treatment

• Combination therapy using HTR2B antagonist (PRX-08066) with CAB significantly inhibits tumor cell proliferation in:

  • HTR2B-expressing pituitary tumor cell lines

  • Xenografted pituitary tumor models

  • Patient-derived samples

Patient stratification data suggests that tumors characterized by upregulated HTR2B/PKC-γ and downregulated BTG2/GADD45A may particularly benefit from this combination approach .

What protocol modifications are recommended for optimal HTR2B detection in Western blotting?

For successful Western blot detection of HTR2B, researchers should consider the following protocol optimizations:

• Sample preparation:

  • For brain tissue: Use RIPA buffer with protease inhibitors and phosphatase inhibitors

  • For cell lines: Include deglycosylation step (with PNGase F) as HTR2B undergoes glycosylation as a post-translational modification

• Protein loading and transfer:

  • Load 20-30 μg of total protein

  • Use PVDF membrane (rather than nitrocellulose) for better retention of hydrophobic transmembrane proteins

  • Transfer at lower voltage (25V) for longer duration (overnight) to improve transfer of membrane proteins

• Antibody conditions:

  • Optimal dilution: 1:200 for most commercial anti-HTR2B antibodies

  • Blocking: 5% non-fat milk in TBST (avoid BSA which may increase background)

  • Incubation time: Overnight at 4°C for primary antibody

• Controls:

  • Positive controls: Mouse brain, rat brain, rat uterus, and human SH-SY5Y neuroblastoma cells have been validated

  • Negative controls: Pre-incubation with 5HT2B Receptor/HTR2B blocking peptide

• Expected band size: The canonical human HTR2B protein appears at approximately 54.3 kDa, though glycosylation may result in higher apparent molecular weights .

How should immunohistochemistry protocols be adapted for HTR2B detection in different tissue types?

Immunohistochemical detection of HTR2B requires tissue-specific protocol adjustments:

For brain tissue (particularly cerebellum):

• Fixation: 4% paraformaldehyde for 24 hours

• Antigen retrieval: Citrate buffer (pH 6.0) for 10 minutes at 95°C

• Antibody dilution: 1:400 for optimal staining of Purkinje cell layers

• Expected pattern: Red staining in neurons of the Purkinje layer and in the molecular layer

• Counterstaining: DAPI for nuclear visualization

For tumor tissue:

• Section thickness: 5 μm is optimal

• Blocking: 10% normal goat serum with 1% BSA

• Primary antibody incubation: 1:200 dilution, overnight at 4°C

• Detection system: Biotin-streptavidin HRP system with DAB substrate provides the best signal-to-noise ratio

• Counterstaining: Hematoxylin (light)

For pituitary tissue:

• Additional permeabilization step with 0.2% Triton X-100

• Extended primary antibody incubation (36-48 hours at 4°C)

• Signal amplification using tyramide signal amplification (TSA) may be necessary for low-expressing samples

What are the key considerations for immunofluorescence studies using HTR2B antibodies?

When performing immunofluorescence with HTR2B antibodies, consider these critical factors:

• Cell preparation:

  • For adherent cells: Culture on poly-L-lysine coated coverslips

  • For suspension cells: Cytospin preparation at 800 rpm for 5 minutes

  • Fixation: 4% paraformaldehyde (10 minutes) is preferred over methanol fixation

• Antibody selection:

  • For membrane localization: Use antibodies targeting extracellular domains (N-terminus)

  • For total protein detection: Antibodies against internal regions may provide stronger signals

• Signal optimization:

  • Permeabilization: 0.1% Triton X-100 (5 minutes) for intracellular epitopes

  • Blocking: 5% normal serum from the species of secondary antibody

  • Antibody incubation: 1:200 dilution, overnight at 4°C

  • Wash steps: Extend to 5× 5 minutes to reduce background

• Visualizing subcellular localization:

  • Co-staining with plasma membrane markers (e.g., Na+/K+ ATPase)

  • Nuclear counterstain (DAPI)

  • Z-stack imaging to confirm membrane vs. cytoplasmic localization

• Controls:

  • Secondary antibody only control

  • Blocking peptide competition

  • Positive control cells (SH-SY5Y neuroblastoma or THP-1 monocytic leukemia cells)

How can flow cytometry be optimized for cell surface detection of HTR2B?

Flow cytometry offers a valuable approach for quantifying cell surface HTR2B expression. For optimal results:

• Cell preparation:

  • Use live, intact cells (avoid permeabilization for cell surface detection)

  • Gentle enzymatic dissociation of adherent cells (avoid trypsin which may cleave surface receptors)

  • Filter cell suspension through a 40 μm strainer to remove aggregates

• Antibody selection:

  • Critical: Choose antibodies specifically targeting extracellular (N-terminal) epitopes

  • Recommended amount: 2.5 μg per 1×10^6 cells

• Staining protocol:

  • Blocking: 10% FBS in PBS (30 minutes on ice)

  • Primary antibody incubation: 30-45 minutes on ice

  • Secondary antibody: Goat-anti-rabbit-FITC (or other fluorophores)

  • Viability dye: Include to exclude dead cells from analysis

• Controls:

  • Unstained cells

  • Secondary antibody only

  • Isotype control

  • Positive control cell line (THP-1 monocytic leukemia cells have been validated)

• Analysis considerations:

  • Gate on viable, single cells

  • Compare median fluorescence intensity (MFI) rather than percentage positive

  • Consider compensation if using multiple fluorescent markers

Following this protocol can achieve successful detection of cell surface HTR2B, as demonstrated in human THP-1 monocytic leukemia cells .

Why might Western blot detection of HTR2B show multiple bands, and how should this be interpreted?

Multiple bands in HTR2B Western blots can result from several biological and technical factors:

Biological causes:

• Post-translational modifications: HTR2B undergoes glycosylation, which can produce bands at higher molecular weights than the predicted 54.3 kDa . Treatment with deglycosylation enzymes before Western blotting can help determine if this is the cause.

• Splice variants: Alternative splicing may generate different HTR2B isoforms. Consult protein databases to identify known variants and their expected sizes.

• Receptor dimerization: G-protein coupled receptors like HTR2B can form dimers or oligomers that may not completely dissociate under standard SDS-PAGE conditions, resulting in higher molecular weight bands.

Technical causes:

• Protein degradation: Partial degradation during sample preparation can produce lower molecular weight fragments. Use fresh samples and additional protease inhibitors.

• Antibody cross-reactivity: Some antibodies may cross-react with other serotonin receptor family members. Compare patterns using different antibodies targeting distinct epitopes of HTR2B.

• Non-specific binding: Especially common with polyclonal antibodies. Optimize blocking conditions (try 5% milk vs. 3% BSA) and increase washing steps.

For proper interpretation:

• The canonical HTR2B protein appears at approximately 54.3 kDa

• Glycosylated forms typically appear between 60-70 kDa

• Verify the specificity of bands using blocking peptide competition assays

• Compare patterns across multiple tissue/cell types with known HTR2B expression profiles

What are the most common false positive/negative results in HTR2B immunodetection and how can they be avoided?

Common false positives:

• Cross-reactivity with other 5-HT receptors: The 5-HT2 family consists of three related receptors (5-HT2A, 5-HT2B, and 5-HT2C) with structural similarities . To avoid:

  • Use highly specific antibodies validated against all three receptors

  • Include negative controls (tissues known to lack HTR2B)

  • Confirm findings with genetic approaches (siRNA knockdown)

• Non-specific binding in brain tissue: Brain tissue often shows high background. To minimize:

  • Use antigen retrieval methods optimized for neural tissue

  • Increase blocking time (2 hours minimum)

  • Include 0.1% Triton X-100 in antibody diluent

  • Use more stringent washing (0.1% Tween-20)

Common false negatives:

• Epitope masking: Fixation or sample preparation may mask HTR2B epitopes. To prevent:

  • Try multiple fixation methods (4% PFA, 10% formalin, methanol)

  • Test different antigen retrieval protocols (heat-induced vs. enzymatic)

  • Use antibodies targeting different regions of the protein

• Low expression levels: HTR2B may be expressed at low levels in some tissues. To address:

  • Increase protein loading for Western blots

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal amplification methods (TSA for IHC/IF)

  • Consider more sensitive detection systems (ECL Prime)

• Receptor internalization: Under certain conditions, HTR2B may internalize, reducing cell surface detection. To account for:

  • Include permeabilization steps when assessing total receptor levels

  • Compare stimulated vs. unstimulated conditions

  • Use antibodies against both extracellular and intracellular domains

How should HTR2B antibody data be interpreted when results differ between detection methods?

Discrepancies between different detection methods are common when studying membrane proteins like HTR2B. Consider these interpretation guidelines:

• Method-specific considerations:

  • Western blot detects denatured protein and is quantitative but loses spatial information

  • IHC/IF preserves spatial context but may have sensitivity limitations

  • Flow cytometry quantifies cell surface expression but lacks subcellular resolution

• Systematic troubleshooting approach:

  • Verify antibody specificity in each method independently

  • Determine if discrepancies are quantitative (signal intensity) or qualitative (presence/absence)

  • Consider physiological state of samples (receptor activation can alter detectability)

• Interpretation framework:

  • For conflicting results between Western blot and IHC/IF: Western blot typically detects total protein regardless of localization, while IHC/IF is influenced by subcellular distribution

  • For discrepancies between native and fixed samples: Fixation may alter epitope accessibility

  • When flow cytometry conflicts with other methods: Consider cell surface vs. total expression

• Resolution strategies:

  • Use orthogonal approaches (mRNA quantification, reporter assays)

  • Employ genetic validation (CRISPR knockout, siRNA)

  • Combine methods (e.g., subcellular fractionation followed by Western blot)

Example resolution: In a study examining HTR2B in pituitary adenomas, investigators resolved discrepancies between Western blot and IHC by using subcellular fractionation, which confirmed that treatment-induced changes affected receptor membrane localization rather than total expression .

How is HTR2B being investigated as an immunomodulatory target in cancer therapy?

Recent groundbreaking research has revealed HTR2B as a promising immunomodulatory target in cancer:

Key findings from 2025 studies:

• HTR2B expression correlates with immunosuppression: Cancer patients with high HTR2B expression show:

  • Enriched gene sets related to T-cell suppression

  • Enhanced angiogenesis and epithelial-mesenchymal transition

  • Dominant macrophage and monocyte infiltration rather than T, B, and NK cells

  • Significant dysfunction of cytotoxic T lymphocyte (CTL) responses

• HTR2B antagonists drive anti-tumor immunity:

  • Administration of HTR2B antagonists restricts tumor growth in immunocompetent but not immunodeficient mice

  • HTR2B antagonism generates tumor antigen-specific immune responses

  • These responses show specificity (controlling growth of target tumors but not unrelated tumors)

• Combinatorial therapy approaches:

  • HTR2B antagonists synergize with immune checkpoint blockers (anti-PD1, anti-PD-L1, anti-CTLA4)

  • Combination therapy significantly enhances IFNγ+granzyme B+ cytotoxic effector CD8 T cell populations within tumors

  • HTR2B antagonists also enhance effectiveness of chemotherapeutic agents like oxaliplatin, 5-fluorouracil, and irinotecan

These findings suggest that HTR2B antagonism represents a novel approach to cancer immunotherapy by converting immunologically "cold" tumors into "hot" tumors with enhanced T cell infiltration and function.

What are the emerging applications of HTR2B antibodies in neuroscience research?

HTR2B antibodies are enabling new insights in neuroscience research:

• Neuroanatomical mapping: Immunohistochemical staining with HTR2B antibodies has revealed specific distribution patterns in the brain, including:

  • Expression in neurons of the Purkinje layer

  • Presence in the molecular layer of the cerebellum

  • Distribution in various brain regions involved in mood regulation

• Neuropsychiatric research: HTR2B is being investigated in:

  • Anxiety and depression models (serotonergic pathways)

  • Impulsivity and behavioral control (HTR2B gene variants)

  • Response to selective serotonin reuptake inhibitors (SSRIs)

• Neurodevelopmental studies: HTR2B antibodies are being used to track:

  • Temporal expression patterns during brain development

  • Region-specific receptor expression in developing neural circuits

  • Potential roles in neuronal migration and circuit formation

• Neuroinflammation: Emerging research indicates HTR2B may play roles in:

  • Microglial activation and function

  • Neuroinflammatory responses

  • Neuron-glia communication

How do HTR2B antibodies contribute to understanding signaling pathway crosstalk in disease contexts?

HTR2B antibodies have become critical tools for elucidating complex signaling networks:

• HTR2B-STAT3 signaling axis: In nonfunctioning pituitary adenomas, HTR2B antibodies helped reveal:

  • Direct interaction between PKC-γ and STAT3 downstream of HTR2B activation

  • HTR2B-mediated activation of the Gαq/PLC/PKC pathway

  • STAT3 phosphorylation and nuclear translocation mechanisms

  • Regulatory role in G2M cell cycle progression

• Serotonin-dopamine system interactions:

  • HTR2B antibodies have helped identify unexpected crosstalk between serotonergic and dopaminergic systems

  • Cabergoline (a dopamine agonist) was found to paradoxically activate pSTAT3 via HTR2B

  • This insight led to rational combination therapy approaches

• Immune signaling integration:

  • HTR2B antibodies have helped map connections between serotonergic signaling and immune regulation

  • HTR2B expression correlates with T-cell suppression, angiogenesis, and epithelial-mesenchymal transition pathways

  • Antagonizing HTR2B leads to enhanced immune checkpoint inhibitor efficacy

These findings demonstrate how HTR2B antibodies contribute to uncovering unexpected pathway interactions, leading to novel therapeutic strategies for cancer and endocrine disorders.